MEASLES VACCINE DEVELOPMENT IN RHESUS MONKEY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：麻疹减毒活疫苗是非常有效的，尽管母源抗体阻止其在6个月前接种。我们正在研究编码麻疹病毒血凝素、融合和核蛋白的DNA疫苗保护新生儿免受麻疹感染的能力。我们还试图确定麻疹病毒的突变，这些突变会导致恒河猴的感染和疾病减弱。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The live, attenuated measles vaccine is very effective, although maternal antibody prevents its administration prior to 6 months of age. We are investigating the ability of a DNA vaccine encoding the measles viral hemaglutinin, fusion and nucleoprotein to protect newborn infants from measles. We are also attempting to define mutations in measles virus that result in attenuated infection and disease in the rhesus monkey.